Alex H Gifford1, Nicole Mayer-Hamblett2, Kelsie Pearson3, David P Nichols4. 1. Pulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, NH, Lebanon, USA; The Dartmouth Institute for Health Policy and Clinical Practice, NH, Lebanon, USA. Electronic address: giffora@hitchcock.org. 2. Cystic Fibrosis Therapeutics Development Network Coordinating Center, Department of Pediatrics, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA, USA. Electronic address: nicole.hamblett@seattlechildrens.org. 3. Cystic Fibrosis Therapeutics Development Network Coordinating Center, Department of Pediatrics, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA, USA. Electronic address: Kelsie.Pearson@seattlechildrens.org. 4. Cystic Fibrosis Therapeutics Development Network Coordinating Center, Department of Pediatrics, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA, USA. Electronic address: David.Nichols@seattlechildrens.org.
Abstract
BACKGROUND: We recognize an unprecedented opportunity to study the effects of withdrawing one or more chronic treatments in people with CF (PwCF) who benefit greatly from CFTR modulator therapy, but feasibility and acceptance of such a study within the community is unknown. METHODS: We surveyed PwCF, their families, and their acquaintances between November 16, 2018, and December 2, 2018, and CF clinicians between December 19, 2018, and January 2, 2019, about treatment withdrawal research. We sought feedback from these groups about their level of interest in this research, the consistency with which they were taking modulator and non-modulator treatments, the ways in which they conceptualized health changes, and what chronic non-modulator treatments they were most interested in stopping. We also asked for stakeholder perspectives on the design of a treatment withdrawal trial, but we intend to report these perspectives elsewhere. RESULTS: Eighty percent (541/675) of CF community respondents and 95% (206/218) of CF clinicians said that a trial of treatment simplification should be performed in the context of highly effective modulator therapy. Most current CFTR modulator users (292/359, 81%) have not stopped another chronic treatment. Worsening lung function by spirometry or increased daily symptoms were important health indicators. PwCF, their families, and/or their acquaintances ranked airway clearance techniques and inhaled antibiotics as the most burdensome treatments. CONCLUSIONS: There is considerable support among the CF community and CF clinicians in the U.S. for controlled trials to assess the safety and impact of treatment simplification in patients taking highly effective modulator therapy.
BACKGROUND: We recognize an unprecedented opportunity to study the effects of withdrawing one or more chronic treatments in people with CF (PwCF) who benefit greatly from CFTR modulator therapy, but feasibility and acceptance of such a study within the community is unknown. METHODS: We surveyed PwCF, their families, and their acquaintances between November 16, 2018, and December 2, 2018, and CF clinicians between December 19, 2018, and January 2, 2019, about treatment withdrawal research. We sought feedback from these groups about their level of interest in this research, the consistency with which they were taking modulator and non-modulator treatments, the ways in which they conceptualized health changes, and what chronic non-modulator treatments they were most interested in stopping. We also asked for stakeholder perspectives on the design of a treatment withdrawal trial, but we intend to report these perspectives elsewhere. RESULTS: Eighty percent (541/675) of CF community respondents and 95% (206/218) of CF clinicians said that a trial of treatment simplification should be performed in the context of highly effective modulator therapy. Most current CFTR modulator users (292/359, 81%) have not stopped another chronic treatment. Worsening lung function by spirometry or increased daily symptoms were important health indicators. PwCF, their families, and/or their acquaintances ranked airway clearance techniques and inhaled antibiotics as the most burdensome treatments. CONCLUSIONS: There is considerable support among the CF community and CF clinicians in the U.S. for controlled trials to assess the safety and impact of treatment simplification in patients taking highly effective modulator therapy.
Authors: Steven M Rowe; Sonya L Heltshe; Tanja Gonska; Scott H Donaldson; Drucy Borowitz; Daniel Gelfond; Scott D Sagel; Umer Khan; Nicole Mayer-Hamblett; Jill M Van Dalfsen; Elizabeth Joseloff; Bonnie W Ramsey Journal: Am J Respir Crit Care Med Date: 2014-07-15 Impact factor: 21.405
Authors: Peter J Mogayzel; Edward T Naureckas; Karen A Robinson; Gary Mueller; Denis Hadjiliadis; Jeffrey B Hoag; Lisa Lubsch; Leslie Hazle; Kathy Sabadosa; Bruce Marshall Journal: Am J Respir Crit Care Med Date: 2013-04-01 Impact factor: 21.405
Authors: Patrick A Flume; Brian P O'Sullivan; Karen A Robinson; Christopher H Goss; Peter J Mogayzel; Donna Beth Willey-Courand; Janet Bujan; Jonathan Finder; Mary Lester; Lynne Quittell; Randall Rosenblatt; Robert L Vender; Leslie Hazle; Kathy Sabadosa; Bruce Marshall Journal: Am J Respir Crit Care Med Date: 2007-08-29 Impact factor: 21.405
Authors: Nicola J Rowbotham; Sherie Smith; Paul A Leighton; Oli C Rayner; Katie Gathercole; Zoe C Elliott; Edward F Nash; Tracey Daniels; Alistair J A Duff; Sarah Collins; Suja Chandran; Ursula Peaple; Matthew N Hurley; Keith Brownlee; Alan R Smyth Journal: Thorax Date: 2017-08-04 Impact factor: 9.139
Authors: N Mayer-Hamblett; S van Koningsbruggen-Rietschel; D P Nichols; D R VanDevanter; J C Davies; T Lee; A G Durmowicz; F Ratjen; M W Konstan; K Pearson; S C Bell; J P Clancy; J L Taylor-Cousar; K De Boeck; S H Donaldson; D G Downey; P A Flume; P Drevinek; C H Goss; I Fajac; A S Magaret; B S Quon; S M Singleton; J M VanDalfsen; G Z Retsch-Bogart Journal: J Cyst Fibros Date: 2020-06-07 Impact factor: 5.482
Authors: David P Nichols; Alex C Paynter; Sonya L Heltshe; Scott H Donaldson; Carla A Frederick; Steven D Freedman; Daniel Gelfond; Lucas R Hoffman; Andrea Kelly; Michael R Narkewicz; Jessica E Pittman; Felix Ratjen; Margaret Rosenfeld; Scott D Sagel; Sarah Jane Schwarzenberg; Pradeep K Singh; George M Solomon; Michael S Stalvey; John P Clancy; Shannon Kirby; Jill M Van Dalfsen; Margaret H Kloster; Steven M Rowe Journal: Am J Respir Crit Care Med Date: 2022-03-01 Impact factor: 30.528
Authors: Jerry A Nick; Nicole Mayer-Hamblett; David P Nichols; Pradeep K Singh; Arthur Baines; Lindsay J Caverly; James F Chmiel; Ronald L GIbson; Jorge Lascano; Sarah J Morgan; George Retsch-Bogart; Lisa Saiman; Hossein Sadeghi; Joanne L Billings; Sonya L Heltshe; Shannon Kirby; Ada Kong Journal: Thorax Date: 2021-10-27 Impact factor: 9.102